Maiken Keson-Brookes

Rubius Therapeutics, Inc.Mural Oncology plc

Insider activity · 24 months0 buys3 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 1 saleJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 2 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (4 ops.)

€25k

Latest filing published 05 Dec 2025 for Mural Oncology plc. Read the official filing

Filing timeline

BuySale

Maiken Keson-Brookes

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Maiken Keson-Brookes: trading record in brief

Maiken Keson-Brookes discloses dealings in 2 companies, chiefly Mural Oncology plc and Rubius Therapeutics, Inc. The record holds 9 filings, for trades running from 29 January 2022 to 5 December 2025.

Every open-market trade on record is a sale: 4 sales worth €25k. Besides market trades, the filings include 3 share grants and 1 option exercise. Since January 2025: no purchases and 2 sales on the market.

On 5 December 2025 came the latest disclosure, a transaction in Mural Oncology plc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.